Clinical Trials

1,100 enrolled

Lung Neoplasms

NCT06931340 2026-03-04

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

1,260 enrolled

Prostatic Neoplasms

NCT03574571 2026-02-27

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

732 enrolled

Prostatic Neoplasms

NCT07432178 2026-02-25

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

2,288 enrolled

Breast Neoplasms

NCT07371897 2026-01-28

SHINE

154 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07366528 2026-01-26

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

387 enrolled

Neoplasms, Stomach Neoplasms

NCT03801876 2026-01-14

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

300 enrolled

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT06908993 2025-12-17

COMET

133 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04193059 2025-11-26

PANSY

1,560 enrolled

Breast Neoplasms

NCT06929286 2025-10-30

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

125 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03264547 2025-09-29

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

446 enrolled

Breast Neoplasms

NCT06320067 2025-09-26

STAMPEDE2

3,360 enrolled

Prostate Cancer Metastatic

NCT02514681 2025-09-10

PRECIOUS

226 enrolled

Breast Neoplasms

NCT00284778 2025-07-24

Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer

150 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01354522 2025-06-15

TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer

204 enrolled

Breast Neoplasms

NCT06996093 2025-05-30

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

2,508 enrolled

Breast Neoplasms

NCT03903835 2025-04-09

ProBio

750 enrolled

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT00446225 2025-03-05

EURTAC

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

500 enrolled

Genital Diseases, Male, Prostatic Diseases

NCT00798070 2024-12-18

PANTHER

2,017 enrolled

Breast Neoplasms, Neoplasms

NCT01957436 2024-11-12

PEACE1

1,173 enrolled

Neoplasms, Prostatic Neoplasms

NCT02578368 2024-11-12

FLOT5

183 enrolled

Stomach Neoplasms

NCT04447352 2024-11-12

PREVENT

200 enrolled

Stomach Neoplasms

NCT04723875 2024-11-01

Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

306 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04158440 2024-07-09

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

501 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT04540692 2024-06-04

NEOSAMBA

444 enrolled

Breast Neoplasms

NCT06411171 2024-05-17

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

36 enrolled

Gastroesophageal Junction Cancer

NCT02509286 2024-05-08

ESOPEC

438 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT05798793 2024-04-02

NEOPCOSCC

309 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT01935778 2024-02-28

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

286 enrolled

Stomach Neoplasms

NCT00630032 2024-02-21

TavIx

762 enrolled 14 charts

Breast Neoplasms

NCT05159193 2024-02-02

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

372 enrolled

Breast Neoplasms

NCT00617656 2024-01-30

BREC

Phase 3 Terminated

382 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02465736 2024-01-16

Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

Phase 3 Unknown

610 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03926091 2023-11-14

CLOVER

Phase 3 Unknown

2,172 enrolled

Breast Neoplasms

NCT06102395 2023-10-30

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

272 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05264896 2023-09-07

Perioperative FLOT vs Adjuvant XELOX for CA Stomach

110 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT05983783 2023-08-09

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

200 enrolled

Prostatic Neoplasms

NCT05430399 2023-07-13

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

349 enrolled

Breast Neoplasms

NCT05883852 2023-06-27

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

1,406 enrolled

HER2 Positive Early Breast Cancer

NCT03919552 2023-06-18

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

482 enrolled

Nasopharyngeal Carcinoma

NCT05901428 2023-06-15

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

1,736 enrolled

Hormone Receptor Positive HER-2 Negative Breast Cancer

NCT05813015 2023-04-14

Study of Comparing of With and Without Sequential Therapy of S-1

70 enrolled

Locally Advanced Gastric Adenocarcinoma

NCT00121992 2023-04-04

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

1,060 enrolled 20 charts

Breast Neoplasms

NCT01257139 2023-04-03

ESOGIA

490 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04139772 2023-03-24

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Phase 3 Unknown

18 enrolled

Metastatic Castration-resistent Prostate Cancer

NCT01763671 2023-03-14

Ultimate

166 enrolled

Lung Neoplasms

NCT00430183 2023-02-09

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

788 enrolled 10 charts

Prostatic Neoplasms

NCT00055731 2023-01-18

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

413 enrolled